Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Actinium Pharmaceuticals Inc (NY: ATNM )

1.423 -0.077 (-5.17%)
Streaming Delayed Price Updated: 12:52 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Actinium Pharmaceuticals Inc

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ATNM Investors Have Opportunity to Join Actinium Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q2 2024
ATNM stock results show that Actinium Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Tumbles 950 Points; ISM Services PMI Surges In July
Via Benzinga
Topics Stocks
Exposures US Equities
Actinium Pharmaceuticals Receives FDA Request For Additional Studies On Leukemia Treatment
FDA rejects Actinium Pharmaceuticals' Phase 3 SIERRA trial for Iomab-B's Biologics License Application due to inadequate support despite achieving a statistically significant primary endpoint. Actinium... 
Via Benzinga
Exposures Product Safety
Nasdaq Tumbles 3%; Tyson Foods Earnings Top Views
Via Benzinga
3 Under-$10 Biotech Stocks That Could Make You Rich
Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis. 
Via InvestorPlace
3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns
These are the clinical-stage biotech stocks to buy, as they represent companies with an attractive product pipeline. 
Via InvestorPlace
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com, a go-to investing platform covering biotech and... 
Via Newsfile
Actinium Presents Exciting Data On Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
Via AB Newswire
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
From FN Media Group LLC
Via GlobeNewswire
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 17, 2024) - Investorideas.com, a go-to investing platform, releases the first... 
Via Newsfile
Actinium Presents First Ever Data Demonstrating Statistically Significant Anti-Tumor Control and Potent Leukemic Cell Killing with Actimab-A in Combination with Leading Menin Inhibitors in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors Combination with leading menin... 
Via FinancialNewsMedia
Actinium Pharmaceuticals (ATNM) Reveals Promising Results from SIERRA Trial at EHA Congress
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024
These are the biotech stocks under $10 that are attractively valued and have potential catalysts in the form of positive clinical trials news 
Via InvestorPlace
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
These are the biotech stocks to buy for a meme rally as they represent companies with positive impending news related to clinical trials. 
Via InvestorPlace
3 Cheap Biotech Stocks to Buy Now: May 2024
Many of these cheap biotech stocks are on their way to achieving FDA approval for their drugs to enter the market. 
Via InvestorPlace
Exposures Product Safety
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
Via AB Newswire
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
Via AB Newswire
ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q1 2024
ATNM stock results show that Actinium Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. 
Via Investor's Business Daily
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
Via AB Newswire
Topics Economy
Exposures Interest Rates
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
Via AB Newswire
Topics Economy
Exposures Interest Rates
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest
Via AB Newswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS